Cookies help us to provide you a better service. In using our services, you agree with our use of cookies. Read More

History

1924
Foundation of BIAL by Álvaro PORTELA
1929
Registration of BIAL first brand: Benzo-Diacol huge success
1962
António Emílio PORTELA became president of BIAL
1978
Launch of Reumon Gel
1979
Luís PORTELA became President of Bial (President & CEO)
1984
1st BIAL Award
1987
Launch of Clavamox
1993
Beginning of R&D activities
1994
Establishment of BIAL Foundation
1996
1st patent application of Eslicarbazepine Acetate
Inauguration of BIAL’s facilities at S. Mamede do Coronado, Trofa
1998
BIAL acquired Aristegui in Spain & founded BIAL Spain
Medimport (Mozambique)
BIAL obtained ISO9001 certification
2001
BIAL obtained ISO14001 certification
2005
BIAL joined EFPIA
BIAL was granted the “Company Award 2005” by AEP
2007
BIAL obtained 4457:2007 R&D certification
Eslicarbazepine Acetate Licensed to Sepracor for US and Canada markets
2008
BIAL-FWA (Ivory Coast) | BIAL-Latin America (Panama) | BIAL-Angola (Angola) Novipharma (Switzerland)
BIAL was granted the “Best Company in the Pharmaceutical Products sector” by EXAME: The Largest & The Best 500
2009
Eslicarbazepine Acetate license to EISAI for European markets
Eslicarbazepine Acetate – 1st launch in the European market
EMA approved Eslicarbazepine Acetate
2010
Eslicarbazepine Acetate - launch in the Portuguese market
BIAL acquired S.A.R.M Allergeni in Italy & founded BIAL Italy
2011
BIAL obtained OHSAS 18001:2007 certification
Luís PORTELA became non executive President and António PORTELA CEO of BIAL
2012
Inauguration of BIAL’s new Unit in Bilbao by his R. H. the Prince of Asturias
BIAL acquired a Business Unit of the Spanish company Juste
2013
Opicapone licensed to Japonese company ONO
FDA approved Eslicarbazepine Acetate
2014
Beginning of APTIOM’s commercialization in the US
2015
FDA approves Aptiom as monotherapy
BIAL initiates business operations in Germany and UK
2016
European Commission approves Opicapone (ONGENTYS®)
2017
BIAL sells immunotherapy allergic área
Opicapone licensed to American Company Neurocrine
2018
Opicapone licensed to Chinese company Wanbang and South Korean company SK Chemicals;
Eslicarbazepine Acetate licensed to South Korean company WhanIn